BRIEF—Sosei signs R&D deal with DyNAbind

Heptares Therapeutics, a subsidiary of Tokyo’s Sosei Group, has entered into a new collaboration with Germany-based DyNAbind.

The firms will work to optimize selective and potent small molecule drug candidates for multiple G-protein-coupled receptor (GPCR) targets.

Sosei’s chief R&D officer Malcolm Weir said: “This exciting collaboration offers an opportunity to enhance further our world-leading StaR technology and structure-based drug discovery platform.”

Sosei retains all rights to advance resulting compounds into discovery and development. Financial terms were not disclosed.